CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 162 enrolled
Drug / intervention
BATdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02055183
NCT02055183N/ACompleted
CompareCT.gov

Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin.

Emergent BioSolutions·observational·Posted Feb 5, 2014·Updated Mar 15, 2024

In Brief

An observational study evaluating BAT for Botulism. Completed, enrolled 162 participants.

Detailed Summary

The purpose of the Registry was to evaluate patient safety following Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) administration in adult and pediatric patients with a confirmed or suspected exposure to botulinum toxin.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBotulism
Countries--
CollaboratorsBiomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 5, 2014
Enrollment StartOct 1, 2014
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.4 years ago

Interventions

BATdrug

Noninterventional, retrospective, observational phase 4 patient Registry